From: Fierce Pharma

By: Eric Sagonowsky

 

 

 

 

 

Lilly Launches Real-World Study to Benchmark Emgality Against Migraine Rivals

Eli Lilly’s CGRP migraine prevention med Emgality trailed its rivals onto the market, but it’s been a force in the dogfight for market share. Now, in an effort to learn more about how physicians choose between the med and its competitors, the company has started a real-world evidence study…(read more).